MY102029A - Human factor viii, compositions containing it, methods and materials for use in its production - Google Patents

Human factor viii, compositions containing it, methods and materials for use in its production

Info

Publication number
MY102029A
MY102029A MYPI87001923A MYPI19871923A MY102029A MY 102029 A MY102029 A MY 102029A MY PI87001923 A MYPI87001923 A MY PI87001923A MY PI19871923 A MYPI19871923 A MY PI19871923A MY 102029 A MY102029 A MY 102029A
Authority
MY
Malaysia
Prior art keywords
factor viii
human factor
materials
production
methods
Prior art date
Application number
MYPI87001923A
Other languages
English (en)
Inventor
Richard Mark Lawn
Daniel Jeffrey Capon
William Irwin Wood
Gordon Allen Vehar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24410850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY102029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MY102029A publication Critical patent/MY102029A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MYPI87001923A 1984-04-20 1987-09-24 Human factor viii, compositions containing it, methods and materials for use in its production MY102029A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60231284A 1984-04-20 1984-04-20
EP85302734A EP0160457B1 (en) 1984-04-20 1985-04-18 Human factor viii, compositions containing it, methods and materials for use in it production

Publications (1)

Publication Number Publication Date
MY102029A true MY102029A (en) 1992-02-29

Family

ID=24410850

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI87001923A MY102029A (en) 1984-04-20 1987-09-24 Human factor viii, compositions containing it, methods and materials for use in its production

Country Status (23)

Country Link
EP (2) EP0160457B1 (en:Method)
JP (2) JP2799338B2 (en:Method)
KR (1) KR850007275A (en:Method)
AR (1) AR241314A1 (en:Method)
AT (1) ATE60087T1 (en:Method)
AU (2) AU601358B2 (en:Method)
CA (2) CA1341468C (en:Method)
DE (1) DE3581312D1 (en:Method)
DK (1) DK164876C (en:Method)
ES (1) ES8607397A1 (en:Method)
FI (1) FI86885C (en:Method)
GR (1) GR850947B (en:Method)
HK (1) HK8395A (en:Method)
HU (1) HU202275B (en:Method)
IE (1) IE57677B1 (en:Method)
IL (1) IL74909A (en:Method)
LU (1) LU88546I2 (en:Method)
MY (1) MY102029A (en:Method)
NL (1) NL940016I2 (en:Method)
NO (1) NO174934C (en:Method)
NZ (1) NZ211824A (en:Method)
PT (1) PT80292B (en:Method)
ZA (1) ZA852864B (en:Method)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
EP0162067B1 (en) * 1983-10-28 1992-07-15 Genetics Institute, Inc. Production of factor viii and related products
US5045455A (en) * 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
DE10399009I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
US4716117A (en) * 1984-10-26 1987-12-29 Chiron Corporation Monoclonal antibodies to factor VIIIC
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (en) * 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
CA1341174C (en) * 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FR2599754B1 (fr) * 1986-06-06 1989-12-29 Transgene Sa Procede de preparation de facteur viii a partir de cellules de mammiferes
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
EP0254076B1 (en) 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
EP0260148A3 (en) * 1986-09-12 1989-06-07 Genentech, Inc. Improved recombinant expression method, vector and transformed cells
EP0302925A4 (en) * 1987-01-30 1989-04-24 Biogen Nv METHOD FOR PRODUCING FACTOR VIII IN LARGE QUANTITIES.
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
FR2642767B1 (fr) * 1989-01-19 1993-10-01 Transgene Sa Vecteurs d'expression de proteines heterologues dans les cellules eucaryotes, lignees cellulaires obtenues et procede pour leur preparation
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US6008193A (en) * 1990-03-02 1999-12-28 Bio-Technology General Corp. Methods of using human von Willebrand factor GPIb binding domain polypeptides
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
RS50743B (sr) * 2000-03-22 2010-08-31 OCTAPHARMA BIOPHARMACEUTICALS GmbH. Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
CN1596310A (zh) * 2001-11-28 2005-03-16 桑多斯有限公司 产生重组多肽的方法
DK1520008T3 (da) 2002-07-09 2012-10-15 Baxter Int Medium frit for dyreprotein til dyrkning af celler
HUE035567T2 (en) 2003-09-30 2018-05-28 Univ Pennsylvania Adeno-associated virus (AAV) clusters, sequences, vectors and applications containing them
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
CN102994549B (zh) 2005-04-07 2015-02-11 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
CN102643777A (zh) 2006-01-04 2012-08-22 巴克斯特国际公司 无寡肽的细胞培养基
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
KR20130040844A (ko) 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 약학적으로 유발된 전이유전자 제거 시스템
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
WO2012112832A1 (en) 2011-02-17 2012-08-23 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
ES3009565T3 (en) 2015-04-16 2025-03-27 Univ Emory Recombinant promoters and vectors for protein expression in liver and use thereof
CN111504887B (zh) * 2020-05-09 2023-05-09 苏州四正柏生物科技有限公司 一种溶血素及其制备方法
US20240043494A1 (en) 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
DE3380848D1 (en) * 1982-08-04 1989-12-21 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
ZA842418B (en) * 1983-03-31 1984-11-28 Scripps Clinic Res Factor viii coagulant polypeptides and monoclonal antibodies to them
EP0162067B1 (en) * 1983-10-28 1992-07-15 Genetics Institute, Inc. Production of factor viii and related products
DE10399009I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS60224492A (ja) * 1984-04-24 1985-11-08 Yuu Honshiyo 異種遺伝子の結合法

Also Published As

Publication number Publication date
GR850947B (en:Method) 1985-07-17
JP2777043B2 (ja) 1998-07-16
FI851497L (fi) 1985-10-21
ATE60087T1 (de) 1991-02-15
KR850007275A (ko) 1985-12-02
NL940016I2 (nl) 2000-08-01
DE3581312D1 (de) 1991-02-21
DK176885A (da) 1985-10-21
FI86885B (fi) 1992-07-15
PT80292A (en) 1985-05-01
AU5295890A (en) 1990-08-30
IL74909A0 (en) 1985-07-31
IL74909A (en) 1992-01-15
NZ211824A (en) 1991-05-28
NO174934B (no) 1994-04-25
AU4134585A (en) 1985-10-24
HU202275B (en) 1991-02-28
IE850998L (en) 1985-10-20
DK164876C (da) 1993-01-18
ES8607397A1 (es) 1986-06-01
PT80292B (pt) 1987-10-20
CA1341395C (en) 2002-10-22
JPH0640942A (ja) 1994-02-15
LU88546I2 (fr) 1995-03-01
EP0160457A1 (en) 1985-11-06
HUT37654A (en) 1986-01-23
ZA852864B (en) 1986-12-30
EP0385558A3 (en) 1990-12-27
EP0385558A2 (en) 1990-09-05
AU601358B2 (en) 1990-09-13
AR241314A1 (es) 1992-05-29
FI86885C (fi) 1992-10-26
NO174934C (no) 1994-08-03
DK164876B (da) 1992-08-31
ES542296A0 (es) 1986-06-01
NL940016I1 (nl) 1994-10-17
NO851563L (no) 1985-10-21
JPS60243023A (ja) 1985-12-03
HK8395A (en) 1995-01-27
JP2799338B2 (ja) 1998-09-17
IE57677B1 (en) 1993-02-24
FI851497A0 (fi) 1985-04-15
EP0160457B1 (en) 1991-01-16
DK176885D0 (da) 1985-04-19
CA1341468C (en) 2004-12-14

Similar Documents

Publication Publication Date Title
MY102029A (en) Human factor viii, compositions containing it, methods and materials for use in its production
EP0192392A3 (en) Insulin receptor, its purification, its production in recombinant cells, dna therefor, antibodies to insulin receptor and their preparation, and pharmaceutical compositions containing them
FI852547L (fi) Framstaellning av faktor viii och daertill hoerande produkter.
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
AU6733487A (en) Mammalian interleukin-4
FI863044A0 (fi) Foerfarande foer framstaellning av erythropoietin.
UA27706C2 (uk) Спосіб одержання гетерологічного поліпептиду
IN162220B (en:Method)
EP0434713A4 (en) Hiv-1 envelope muteins lacking hypervariable domains
NZ188838A (en) Dna coding for microbial expression of mammalian polypeptide recombinant microbial cloning vehicle
HUT40145A (en) Process for producing polypeptides and pharmaceutical compositions containing them
EP0182448A3 (en) Production of factor viii and related products
YU78194A (sh) Dna sastav protein kompleksa i postupak za dobijanje rekombinovanog protein kompleksa
ES8504255A1 (es) Procedimiento para la produccion de una hormona de crecimiento de porcino.
SE8701934L (sv) Okad expression av humant interleukin-2 i deggdjursceller
DE69233463D1 (de) Expression und reinigung von kloniertem humanen alpha-fetoprotein
IL129139A0 (en) Vertebrate smoothened proteins
ES8802441A1 (es) Procedimiento para preparar laminina humana
IL124939A0 (en) Vector for expression of n-terminally extended proteins in yeast cell
KR880009127A (ko) 용성 성숙 hIL-β 및 변경된 생물학적 활성을 갖는 유도체를 이 콜라이에서 고도로 발현시키는 플라즈미드 및 그 방법
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
ES8606402A1 (es) Un procedimiento para preparar una molecula de adn recom- biante
IL76150A (en) Derivatives of aminochromancarboxylic acid and their preparation
IL74620A (en) Genetic expression of somatostatin as hybrid polypeptide